Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients

Overview

The aim of this study is to evaluate the preliminary safety and performance of a low-cost locally-made Venturi-based Non-invasive Positive Pressure Ventilator (NIPPV) device for hypoxemic COVID-19 patients. The device administers Continuous Positive Airway Pressure (CPAP) therapy using the jet-mixing or Venturi effect to increase the volume flow rate of oxygenated air from a pressurized cylinder by entraining the atmospheric air. To provide CPAP therapy, this high flow of oxygenated air is delivered to the patient via a low-cost non-vented mask with a tight seal with a High-Efficiency Particulate Air (HEPA) filter connected to the exhalation limb. The tight seal and HEPA filter ensures a minimal risk of aerosol generation and thus the device can be used without a negative pressure room. The system consists of the developed Venturi-based flow-generator, a standard 22mm breathing tube, a standard Y-connector, a non-vented CPAP mask (e.g., snorkel mask, helmet), a HEPA filter, and a Positive End Expiratory Pressure (PEEP) valve. The bench-top testing of the device is done in the laboratories of BUET and was verified that the device performs within the CPAP guidelines provided by the Medicines and Healthcare products Regulatory Agency (MHRA), UK. This study aims to assess the safety of and efficacy of the device in three different steps: (1) design validation, (2) clinical feasibility and (3) pilot clinical trial for safety and efficacy evaluation. Only if the device successfully passes the parts 1 and 2, the investigators will proceed to the final clinical trial in step 3. In this final step, the investigators aim to conduct a randomized controlled trial (RCT) evaluating for non-inferiority of the CPAP intervention compared to standard HFNO treatment. The number of ventilator-free days will be used as the primary outcome for efficacy, while patient recovery, death, or need of intubation and other adverse events will be used as secondary outcomes.

Full Title of Study: “Safety and Efficacy Evaluation of a Low-cost CPAP Device for Hypoxemic COVID-19 Patients: A Pilot Study”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: July 9, 2021

Interventions

  • Device: High Flow Nasal Oxygen (HFNO) treatment
    • Administration of High Flow Nasal Oxygen (HFNO) to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). Adjust flow-rate and FiO2 as per standard HFNO treatment protocol.
  • Device: Continuous Positive Airway Pressure (CPAP) therapy using OxyJet
    • Administer CPAP to patients who did not respond to standard low-flow oxygen therapy (non-rebreather mask on 15L/min). CPAP initiated with FiO2 at 40% and a 10cm PEEP. Titrate PEEP to 15 cm if required. Deliver additional oxygen via secondary port if a higher FiO2 is required.

Arms, Groups and Cohorts

  • Active Comparator: High Flow Nasal Oxygen (HFNO) treatment
  • Experimental: Continuous positive airway pressure (CPAP) therapy using OxyJet

Clinical Trial Outcome Measures

Primary Measures

  • Number of ventilator-free days
    • Time Frame: 10 days
    • The total number of days the patient was able to avoid being placed under a mechanical ventilator.

Secondary Measures

  • Recovery of the patient
    • Time Frame: 30 days
    • The event that the patient has recovered and released from the hospital within 30 days.
  • Death or need of intubation
    • Time Frame: 10 days
    • The event that the patient dies or requires to be placed under a mechanical ventilator.
  • Oxygen toxicity or other adverse events
    • Time Frame: 10 days
    • Oxygen toxicity or other adverse event rating according to the CTCAE scale (1-5)

Participating in This Clinical Trial

Inclusion Criteria

  • Age ≥ 18 years – Confirmed or suspected COVID-19 patient (by RT-PCR) having severe pneumonia and hypoxemia (SpO2 ≤90%) who did not respond to standard oxygen therapy (non-rebreather mask on 15L/min at 100% FiO2). Exclusion Criteria:

  • Severely hypoxemic patients (SpO2≤85%) – Patients with low respiratory drive or requiring cardiopulmonary resuscitation – Patients with contraindications for CPAP – Pregnant status – Age > 65 years

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bangladesh University of Engineering and Technology
  • Collaborator
    • Dhaka Medical College
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Dr. Taufiq Hasan, PhD, Principal Investigator, Bangladesh University of Engineering and Technology
    • Dr. Robed Amin, MBBS, FCPS, Principal Investigator, Dhaka Medical College

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.